How can health technology assessment support our response to public health emergencies?

Aparna Ananthakrishnan1*, Alia Cynthia Gonzales Luz1, Sarin KC1, Leslie Ong2, Cecilia Oh2, Wanrudee Isaranuwatchai1,3, Saudamini Vishwanath Dabak1, Yot Teerawattananon1,4 and Hugo C. Turner5

Abstract
Public health emergencies (PHEs), such as the COVID-19 crisis, are threats to global health and public order. We recommend that countries bolster their PHE responses by investing in health technology assessment (HTA), defined as a systematic process of gathering pertinent information on and evaluating health technologies from a medical, economic, social and ethical standpoint. We present examples of how HTA organizations in low- and middle-income countries have adapted to supporting PHE-related decisions during COVID-19 and describe the ways HTA can help the response to a PHE. In turn, we advocate for HTA capacity to be further developed globally and for increased institutional acceptance of these methods as a building block for preparedness and response to future PHEs. Finally, the long-term potential of HTA in strengthening health systems and embedding confidence and transparency into scientific policy should be recognized.

Keywords: Health technology assessment, Public health emergencies, COVID-19, Health policy, Economic evaluation, Evidence-informed policy-making, Universal health coverage, Pandemic preparedness

Introduction
Public health emergencies (PHEs) are threats to global health, healthcare systems and public order that can arise from several causes, including the outbreaks of contagious, life-threatening diseases, natural disasters, among others [1]. In January 2020, the COVID-19 outbreak in Wuhan, China, was declared a public health emergency of international concern (PHEIC) by the World Health Organization (WHO). COVID-19 has since been recognized as a pandemic, with its crippling impact transcending national boundaries and paralyzing global freedoms and economies. The current crisis has shown that a PHE of this scale is rarely limited to health outcomes alone and quickly escalates into an economic, ethical and social catastrophe [2]. Since the start of the pandemic, decision-makers have had to make urgent recommendations about the use of pharmaceutical and non-pharmaceutical interventions (NPIs) (such as national and regional border closures, social distancing measures including commercial and business restrictions, personal protection strategies such as masks and hand hygiene) as well as, more recently, COVID-19 vaccines. Each of these decisions have required a careful balance, such as between implementing strict public health measures while protecting the economy and livelihoods, between public safety and individual freedoms, and in a broader sense, between short-term and long-term regional and global development.

For policy responses to be effective and accrue higher benefits than costs, they must be tailored to local settings and consider all potential intended and unintended...
How can HTA contribute to a better PHE response?

Prior to the pandemic, agencies conducting HTA supported their governments on several national-level policies, a majority of which focused on chronic health conditions. However, since 2020, HTA has contributed to addressing COVID-19 issues in several ways. This led to an interest in and consideration of ways in which the HTA approach can be applied to support the response to emergencies. The following are some examples:

- Generating and gathering evidence to support timely and informed decisions
- How can HTA contribute to a better PHE response?

In this paper, we focus on select examples from HTA organizations in low- and middle-income countries (LMICs) in adapting their existing expertise, networks and resources to support PHE-related decisions. These are based on a three-part webinar series titled “Knowledge Exchange in the time of COVID-19: Using Evidence to Address Health Care Challenges in Low- and Middle-Income Countries” organized by the Access and Delivery Partnership (ADP) and the Health Intervention and Technology Assessment Program (HITAP) [12]. The knowledge gained from the webinar series as well as literature showcasing the value of HTAs in informing policy decisions [13–15] inspires our call for strengthening HTA processes and their institutionalization to address ongoing and future prioritization issues.

Before the pandemic, agencies conducting HTA supported their governments on several national-level policies, a majority of which focused on chronic health conditions. However, since 2020, HTA has contributed to addressing COVID-19 issues in several ways. This led to an interest in and consideration of ways in which the HTA approach can be applied to support the response to emergencies. The following are some examples:

- Generating and gathering evidence to support timely and informed decisions
- How can HTA contribute to a better PHE response?

In this paper, we focus on select examples from HTA organizations in low- and middle-income countries (LMICs) in adapting their existing expertise, networks and resources to support PHE-related decisions. These are based on a three-part webinar series titled “Knowledge Exchange in the time of COVID-19: Using Evidence to Address Health Care Challenges in Low- and Middle-Income Countries” organized by the Access and Delivery Partnership (ADP) and the Health Intervention and Technology Assessment Program (HITAP) [12]. The knowledge gained from the webinar series as well as literature showcasing the value of HTAs in informing policy decisions [13–15] inspires our call for strengthening HTA processes and their institutionalization to address ongoing and future prioritization issues.

In this paper, we focus on select examples from HTA organizations in low- and middle-income countries (LMICs) in adapting their existing expertise, networks and resources to support PHE-related decisions. These are based on a three-part webinar series titled “Knowledge Exchange in the time of COVID-19: Using Evidence to Address Health Care Challenges in Low- and Middle-Income Countries” organized by the Access and Delivery Partnership (ADP) and the Health Intervention and Technology Assessment Program (HITAP) [12]. The knowledge gained from the webinar series as well as literature showcasing the value of HTAs in informing policy decisions [13–15] inspires our call for strengthening HTA processes and their institutionalization to address ongoing and future prioritization issues.

In this paper, we focus on select examples from HTA organizations in low- and middle-income countries (LMICs) in adapting their existing expertise, networks and resources to support PHE-related decisions. These are based on a three-part webinar series titled “Knowledge Exchange in the time of COVID-19: Using Evidence to Address Health Care Challenges in Low- and Middle-Income Countries” organized by the Access and Delivery Partnership (ADP) and the Health Intervention and Technology Assessment Program (HITAP) [12]. The knowledge gained from the webinar series as well as literature showcasing the value of HTAs in informing policy decisions [13–15] inspires our call for strengthening HTA processes and their institutionalization to address ongoing and future prioritization issues.

In this paper, we focus on select examples from HTA organizations in low- and middle-income countries (LMICs) in adapting their existing expertise, networks and resources to support PHE-related decisions. These are based on a three-part webinar series titled “Knowledge Exchange in the time of COVID-19: Using Evidence to Address Health Care Challenges in Low- and Middle-Income Countries” organized by the Access and Delivery Partnership (ADP) and the Health Intervention and Technology Assessment Program (HITAP) [12]. The knowledge gained from the webinar series as well as literature showcasing the value of HTAs in informing policy decisions [13–15] inspires our call for strengthening HTA processes and their institutionalization to address ongoing and future prioritization issues.

In this paper, we focus on select examples from HTA organizations in low- and middle-income countries (LMICs) in adapting their existing expertise, networks and resources to support PHE-related decisions. These are based on a three-part webinar series titled “Knowledge Exchange in the time of COVID-19: Using Evidence to Address Health Care Challenges in Low- and Middle-Income Countries” organized by the Access and Delivery Partnership (ADP) and the Health Intervention and Technology Assessment Program (HITAP) [12]. The knowledge gained from the webinar series as well as literature showcasing the value of HTAs in informing policy decisions [13–15] inspires our call for strengthening HTA processes and their institutionalization to address ongoing and future prioritization issues.
Appraising the value of decisions Governments aim to maximize the health outcomes of their investments and collating such evidence even before interventions are launched in the market can be critical in PHEs. One approach that is being piloted across countries is early HTA, defined as “all methods used to inform industry and other stakeholders about the potential value of new medical products in development, including methods to quantify and manage uncertainty” [19, 20] which has been useful in exploring the optimal mix of COVID-19 vaccines and NPIs. HTA agencies in Kenya, Thailand and Singapore conducted an assessment of hypothetical COVID-19 vaccines based on existing vaccine product profiles to understand at which levels and types of vaccine efficacy (e.g. preventing transmission, severe disease or disease contraction), and their combination with NPIs, would best address their respective countries’ healthcare needs [20]. This type of research is useful not only to generate contextually relevant evidence but also to discuss issues of vaccine development and procurement with industry and supranational initiatives such as the COVID-19 Vaccines Global Access (COVAX) [21]. Countries such as Lao People’s Democratic Republic, Ghana and the Philippines are also interested in using HTA to conduct economic evaluations of COVID-19 vaccines to inform prioritization of target populations and the adaptation of vaccine strategies to address emerging disease variants, among others. Studies on the cost-effectiveness of different NPIs have also been a promising area of research; for example, in India, hand hygiene was found to be cost-effective, while public avoidance of surgical masks and respirator use “could save resources” [22].

The substantial economic impact of COVID-19 (with estimates ranging from US$ 77 billion to US$ 2.7 trillion globally [23]) is important to factor into policy decisions as well. Many NPIs such as social distancing, national lockdowns and border closures have significant financial implications. Given that the poor and vulnerable groups are often the hardest hit during PHEs (for example, around 22 million people in sub-Saharan Africa are estimated to be pushed into extreme poverty, with the cost likely falling disproportionately on women, who globally lost around US$ 800 billion in income in 2020 [23, 24]), the inclusion of ethical and social considerations within the HTA process ensures that these populations can be accounted for.

Identifying knowledge gaps and priority research areas Urgent national responses to the COVID-19 pandemic have meant that much of the available health resources have been channelled away from key priority areas, exacerbating critical gaps within the healthcare system. This has compelled governments and healthcare decision-makers to focus on priority areas and implement efficient, streamlined efforts to adequately deliver all existing healthcare demands, including COVID-19. Here, HTA research has been able to support governments in understanding these challenges, as well as informing decisions concerning resource allocation [25]. In India, for example, Prinja et al. estimated a 2.5–3.8% increase in deaths from cervical cancer due to delays in diagnosis and treatment [26]. This type of research can identify clinical areas which require closer monitoring and evaluation to ensure that health outcomes can be stabilized and even improved. On the other hand, it also highlights areas of lower priority or low-value care, for example, “medical services that provide little to no clinical benefit or may cause harm to patients such as antibiotic use for a likely uncomplicated viral infection or imaging for nonspecific low-back pain” [27]. The pandemic could be a catalyst for health professionals and policy-makers to re-prioritize resource allocation or re-evaluate the values that govern decision-making processes for resource allocation [27–30]. Oncology practices in Canada, the United Kingdom, and the United States, for example, now use a “priority-based approach to cancer care”, whereby treatments with clear evidence of improved survival or quality of life are prioritized. This approach has led to a significant reduction in the use of treatments which exhibit small clinical benefits but a high probability of hospitalization and severe side effects. Such efforts aim to balance clinical needs of the patient with requisite treatment while respecting resource limitations and social distancing without compromising clinical benefit [29, 31].

Stronger governance and policy response Established HTA processes can be adapted in the context of a PHE, contributing to stronger governance and policy response. In this context, the HTA principles of transparency and accountability of both researchers and policy-makers are particularly important. For example, based on HTA processes, guidance regarding the use of modelling for informing policy responses to COVID-19 policy was developed [32]. This included standards on how the outputs of the modelling are reported and guidance on facilitating collaboration between modellers/researchers and decision-makers [32], to promote the use of modelling evidence to inform decision-making. This highlights the importance of established HTA processes in facilitating the effective use of evidence and knowledge to inform a comprehensive policy response to PHEs.

Legitimizing government decisions and instilling public trust The process used within HTA is designed to be transparent and inclusive. This can be vital for health policies to be trusted, understood and accepted by stakeholders, including the general public. In Thailand, for instance, HITAP developed a prioritization protocol in the event of shortages of critical care and intensive care
units resulting from a sudden increase in the number of severe COVID-19 patients. With the extensive involvement of relevant stakeholders (including religious leaders, clinicians and ethicists) in the decision-making process, the overarching need to prioritize “maximizing total benefits for the society” was identified and agreed upon as the primary ethical principle guiding the decision-making for critical care resources [33]. These types of consensus-building across prioritization and decision-making processes are vital and must be transparently communicated to broader stakeholder groups such as the public through open lines of communication. Another recent example is a regional study from Asia which analysed vaccine certification uptake through public and institutional surveys, allowing citizen participation and support for government policy-making on the issue from these results [34]. This builds confidence in and bolsters the government’s efforts to address challenging healthcare needs during emergencies. An inclusive and participatory approach can be key to policy acceptance, given the sensitive nature of the issue and the potential risk of public distrust. Unverified and incorrect information can spread quickly and widely over the course of PHEs, impeding public health responses and leading to further disease spread; this phenomenon of too much or harmful misinformation during a PHE is referred to as an “infodemic” by WHO [35, 36]. For example, fake news, misinformation and conspiracy theories have skyrocketed since the beginning of the COVID-19 pandemic, fuelled by the ubiquity of social media [12]. The transparent and evidence-based approaches used within the HTA process can help reduce the risk and spread of such misinformation [37, 38].

The preceding examples collectively illustrate the multiple ways in which HTA, as an institutional approach and as a scientific discipline, can help ensure a country is well placed to address PHEs. This also highlights that HTA is not simply about economic evaluations but a wider framework for the evaluation and use of evidence to inform decision-making.

Conclusions
The COVID-19 pandemic has re-emphasized the value of data to maximize health outcomes. The novelty of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has meant that many aspects associated with it are constantly evolving, including critical information on viral mutations, efficacy and side effects of treatments and vaccines [39]. All these pieces of evidence have significant implications on social and economic policies and practices. Scientific approaches with the capability of including such wide-ranging evidence are therefore essential to inform decision-making in times of crisis. In this paper, we suggest HTA is one such approach as it operates within a framework that recognizes many vital parameters and interactions of evidence-informed decision-making. In support, we reference several examples to show that well-established HTA processes and techniques have been able to support immediate, actionable structures for pandemic response. In addressing our current crisis, HTA processes have facilitated the flow of research skills across disciplines and departments, breaking long-standing silos within healthcare research. They have also shown promise in offering adaptive frameworks to suit contextual requirements, especially useful for resource-constrained settings [40].

That said, HTA is by no means a panacea. One common criticism is the complexity of HTA and the lack of clear guidance for the evaluation of various interventions; Bluher et al. (2019) outline these issues using the example of medical devices in the European Union. For novel crises such as COVID-19, this might require urgent standards to be established and updated with changing circumstances [41]. As an analytic approach relying on diverse, yet specific, knowledge types and contributing stakeholders, HTA processes also require strong knowledge generation and epistemological systems to be in place, which are especially challenging in under-resourced contexts [42]. Importantly, HTA mechanisms are ensconced within the wider ecosystem of economic and political interests which can strongly influence scientific decision-making. For instance, differential power relations between stakeholder groups, particularly in less transparent HTA systems, could result in limited inclusion of the views of marginal groups across the entire process; an important example is patient involvement within HTA [43, 44]. Institutionalizing HTA processes within this macrocosm, such as by establishing HTA research agencies, requires strong political and institutional buy-in, potentially with a legislative foundation that embeds the process of HTA into policy-making [45]. Such strong leadership is also vital in ensuring that all findings and recommendations from HTA processes are appropriately interpreted, accepted, communicated and implemented, after which they are consistently monitored and fed back into the process for improved decisions. For instance, good national COVID-19 performance has not necessarily followed conventional assumptions wherein higher-income countries outperform those less affluent [46]; this could be considered a function of societal values in priority-setting impacted by the influences of interest groups and underlying societal structures [47]. The secure mediatory presence of an independent, interdisciplinary, technical agency to holistically inform policy actions and receive support from institutional or legal mandates has shown to be a useful
arrangement, especially in times of emergencies. As we expand our understanding of the public health discipline to recognize other PHEs such as gun violence, antimicrobial resistance, air pollution and climate change events as realities, there is growing interest in the ability of HTA to comprehensively address these questions.

In immediate progress, strong research collaborations during the pandemic across disciplines have been able to recognize and learn from shortfalls of current modelling methods and HTA systems [48]. HTA agencies and interest groups are taking steps to prepare adaptable HTA methodologies that respond to urgent needs despite the paucity of data and the rapid changes in information that are characteristic of pandemics or other health emergency situations. For example, the "Best-practice guidance for the health technology assessment of diagnostics and treatments for COVID-19" shares recommendations on the use of "living" clinical reviews and other HTA models that analyse newly published data as they are produced and reduce duplication efforts [49]. Outlining similar pragmatic approaches for HTA agencies, the document also suggests simpler methods such as cost-consequence analyses to assess value-for-money considerations without using frequently unavailable utility values. These adaptations are demonstrative of customization within the discipline and also deeply valuable for LMICs that face such challenges even during nonemergency situations. A key example of technical learning in the field includes the recognition that economic evaluations for COVID-19 policy responses, and arguably other PHEs, are inappropriate in limiting their analyses to the health systems perspective alone and warrant a society-wide calculation, meaning that non-health costs/benefits of NPIs and other such measures are just as critical to analyse [50]. In their paper, Painter et al. further elaborate on the important potential of economic evaluations on COVID-19 vaccines and the technical considerations in conducting these studies, building on case experiences from Singapore and Thailand. Another example relates to the weights given to different cost inputs within calculations based on immediate disease-related conditions; in situations where intensive care unit (ICU) beds are fully occupied, they are costed with greater opportunity costs than other factors such as labour and materials, given their fundamental life-saving ability for patients [51]. These developments showcase promise for the approach in serving as a ready tool during crises.

As the pandemic continues and new health security challenges emerge, healthcare practitioners and policy-makers are required to regularly re-prioritize their efforts. This pattern has been mirrored by HTA agencies as well, where important HTA research on non-pandemic health priorities and routine services including immunizations such as rotavirus and pneumococcal vaccines have been paused. This paper argues that there is an imminent need to build technical expertise and capacity for HTA globally, as the concepts and processes of HTA hold immense value in prioritizing and addressing policy-relevant questions. The unique aspect of HTA in aggregating inputs from diverse stakeholders, generating and appraising such relevant evidence and then communicating the final results to decision-makers, including the public, is urgently required during PHEs. From COVID-19 and other similar crises, it is clear that these practices are fully aligned with recommended actions for governments in response to any or every PHE. The benefits of applying HTA concepts using existing infrastructure (even without dedicated HTA bodies) for decision-making are especially useful in LMICs which face a chronic shortage of healthcare resources and incur higher opportunity costs from poor decisions. Over the course of the pandemic, regional and global networks for learning and sharing have emerged as important avenues of translational research and evidence use. For instance, collaborative networks and platforms (such as HTAAsiaLink, Guide to Health Economics Analysis and Research, and ADP/HITAP knowledge exchange initiatives on HTA that include the webinar series on COVID 19 among others [12, 52]), foster participation and learning for policy-makers, researchers and other stakeholders involved in HTA processes. They have offered upskilling opportunities such as trainings and workshops as well as lessons sharing events on important issues such as policy advocacy, guideline development and other contextual challenges. We emphasize that a commitment for greater financial resources towards HTA, while reinforcing political will and institutional acceptance of these methods are building blocks for preparedness and response to future PHEs. More importantly, we must recognize the long-term potential of HTA in strengthening health systems and embedding confidence and transparency into scientific policy decision-making. These impacts are far-reaching as an important component of universal health coverage (UHC) and, broadly, the Sustainable Development Goals [53].

Abbreviations
ADP: Access and Delivery Partnership; COVAX: COVID-19 Vaccines Global Access; HITAP: Health Intervention and Technology Assessment Program; HTA: Health technology assessment; LMICs: Low- and middle-income countries; NPIs: Non-pharmaceutical interventions; PHEs: Public health emergencies; PHEIC: Public health emergency of international concern; UHC: Universal health coverage; WHO: World Health Organization.

Acknowledgements
The content of this article draws on the presentations and discussions over the course of the three-part webinar series titled "Knowledge Exchange in the time of COVID-19: Using Evidence to Address Health Care Challenges in
Low- and Middle-Income Countries” organized by the Access and Delivery Partnership (ADP) and the Health Intervention and Technology Assessment Program (HITAP). The authors thank the following researchers and speakers for sharing valuable insights from their work as part of this series: Dr Shankar Prinja, Dr Melissa Guerrero, Professor Jesse Boardman Bump, Professor Ole Frithjof Norheim, Dr Brian Asare, Ms Rachel Archer, Dr Ruth Lopert, Dr Nettepis Suchonwanich, Mrs Joycelyn Azeez, Dr Merawai Aragaw, Dr Suwit Wibulpolprasert, Mrs Deepika Adhikari, Ms Jamaica Briones, Dr Auliya Suwantika, Dr Rukmanee Butchon and Christopher Painter. All information on the series is available at https://adphhealth.hitap-webinar.org.

Author contributions
AA, AL, SKC and HCT conceptualized the outline of the paper and authored the first draft. YT, SD, WI, CO and LO provided in-depth review of the first draft and added suggested edits to the main text. All authors read and approved the final manuscript.

Funding
HCT acknowledges funding from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the United Kingdom Medical Research Council (MRC) and the United Kingdom Foreign, Commonwealth & Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. The Health Intervention and Technology Assessment Program (HITAP) is a semi-autonomous research unit in the Ministry of Public Health, Thailand, that supports evidence-informed priority-setting and decision-making for healthcare. HITAP is funded by national and international public funding agencies. HITAP is supported by the Access and Delivery Partnership (ADP), which is hosted by the United Nations Development Programme (UNDP) and funded by the Government of Japan to strengthen capacity for evidence-informed decision-making. HITAP is supported by the Health Systems Research Institute (HSRI) to conduct a study on operationalizing a regional centre for disease prevention and control and is collaborating with the Rockefeller Foundation to build capacity for infectious disease modelling to inform policy. The findings, interpretations and conclusions expressed in this article do not necessarily reflect the views of the funding agencies.

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Nonthaburi, Thailand. 2 Access and Delivery Partnership, United Nations Development Programme (UNDP), Bangkok, Thailand. 3 Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada. 4 Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. 5 MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial College London, London, United Kingdom.

Received: 30 December 2021 Accepted: 3 October 2022 Published online: 04 November 2022

References
1. Magnuson R. Advancing the right to health: the vital role of law. Adv Right to Heal Vital Role Law, World Heal Organ Switz. 2017.
2. Nicola M, Alsafi Z, Sohrabi K, Kerwan A, Al-Jabir A, Iosifidis C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): a review [Internet]. Int J Surg. 2020;78:185–93.
3. Rocha R, Atun R, Massuda A, Rache B, Spinola P, Nunes L, et al. Effect of socioeconomic inequalities and vulnerabilities on health-system preparedness and response to COVID-19 in Brazil: a comprehensive analysis. Lancet Glob Heal [Internet]. 2021;9(6):e782–92.
4. Han E, Mei Jin Tan M, Turk E, Sridhar D, Leung GM, Shibuya K, et al. Lessons learnt from easing COVID-19 restrictions: an analysis of countries and regions in Asia Pacific and Europe. Lancet [Internet]. 2020;396:1526–34.
5. Udw-Phillips M, Lantz PM. Trust in public health is essential amid the COVID-19 pandemic. J Hosp Med. 2020;15(7):431–3.
6. Devine D, Gaskell J, Jennings W, Stoker G. Trust and the coronavirus pandemic: what are the consequences of and for trust? An early review of the literature. PLoS Publ Rev. 2020;14(7):e9296884.
7. India, Brazil and the human cost of sidelining science. Nature. 2021; 593: 7–8.
8. WHO | HTA Definitions [Internet]. [cited 2021 Mar 5]. Available from: https://who.int/health-technology-assessment/about/Defining/en/.
9. O’Rourke B, Oortwiijn W, Schiller T. The new definition of health technology assessment: a milestone in international collaboration [Internet]. Int J Technol Assessment Health Care. 2020;36:187–90. https://doi.org/10.1017/S0266642320000215.
10. iDSI Reference Case for Economic Evaluation | iDSI [Internet]. [cited 2021 Apr 9]. Available from: https://idsihealth.org/resource-items/idsi-reference-case-for-economic-evaluation/#principles.
11. What is HTA?—Health Technology Assessment Central [Internet]. [cited 2021 Mar 5]. Available from: https://www.htacentral.org/what-is-HTA/.
12. Using evidence to address healthcare challenges [Internet]. [cited 2021 Sep 14]. Available from: https://adphhealth.org/hitap-webinar/.
13. Sandmann FG, Davies NG, Vassall A, Edmunds WJ, Jit M, Sun FY, et al. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation. Lancet Infect Dis [Internet]. 2021;21(7):962–74.
14. Ruggeri M, Cadeddu C, Roazzi P, Mandolini D, Grigioni M, Marchetti M. Multi-criteria-decision-analysis (MCDA) for the horizon scanning of health innovations an application to COVID 19 emergency. Int J Environ Res Public Health [Internet]. 2020;17(12):1–9.
15. Rezapour A, Soaresrafil A, Peighambari MM, Heidarali M, Tashakori-Miyanroudi M. Economic evaluation of programs against COVID-19: a systematic review. Int J Surg [Internet]. 2021;85:10–8.
16. HTA and the COVID-19 pandemic | HTA [Internet]. [cited 2021 Mar 5]. Available from: https://hta.doh.gov.ph/2020/10/02/hta-and-the-covid-19-pandemic/.
17. Status of Assessments | HTA [Internet]. [cited 2021 May 17]. Available from: https://hta.doh.gov.ph/status-of-health-technologies-assessments/.
18. Luangasanatip N, Pan-Ngum W, Prawjaeng J, Saralaamba S, White L, Aguas R et al. Optimal vaccine strategy to control COVID-19 pandemic in middle-income countries: Modelling case study of Thailand. [pre-print] [cited 2022 June 17] Available from: https://assets.researchsquare.com/files/rs-270035/v1_covered.pdf?c=1631855596.
19. Izerman MJ, Koffenberg H, Fennwick E, Krah M. Emerging use of early health technology assessment in medical product development: a scoping review of the literature [Internet]. Pharmacoeconomics. 2017;35:727–40.
20. Painter C, Teenawattananon Y, Chakdiovou K, Clapham H. Early Health Technology Assessment for a COVID-19 Vaccine | Center For Global Development [Internet]. 2020 [cited 2021 May 17]. Available from: https://www.cgdev.org/blog/early-health-technology-assessment-covid-19-vaccine.
21. Teenawattananon Y, Dabak SY. COVID vaccination logistics: five steps to take now. Nature [Internet]. 2020;587(7833):194–6.
22. Bagepally BS, Haridoss M, Natarajan M, Jeyashree K, Ponnaiah M. Cost-effectiveness of surgical mask, N-95 respirator, hand hygiene and surgical mask with hand hygiene in the prevention of COVID-19: cost effectiveness analysis from Indian context. Clin Epidemiol Glob Heal. 2021;1(10):100702.
24. COVID-19 cost women globally over $800 billion in lost income in one year. [Oxfam International [Internet]. 2021 [cited 2021 Jul 1]. Available from: https://www.oxfam.org/en/press-releases/covid-19-cost-women-globally-over-800-billion-lost-income-one-year.

25. Sarin KC, Ananthakrishnan A, Painter C, Butani D, Teeravattananon Y. Research collaboration is needed to inform quarantine policies for health-care workers. Lancet. 2021. https://doi.org/10.1016/S0140-6736(21)02124-1.

26. Gupta N, Chauhan AS, Prinja S, Pandey AK. Impact of COVID-19 on outcomes for patients with cervical cancer in India. JCO Glob Oncol. 2021;7:716–25.

27. Sorensen C, Japinga M, Crook H, McClellan M. Building a better health care system post-COVID-19: steps for reducing low-value and wasteful care. Njm Catal Innov Care Deliv [Internet].

28. The COVID-19 Pandemic Can Help Us Understand Low-Value Health Care | Health Affairs [Internet]. [cited 2021 Mar SJ]. https://doi.org/10.1377/hblog20201023.522078/full.

29. Gyawali B, Poudyal BS, Eisenhauer EA. Covid-19 pandemic—an opportunity to reduce and eliminate low-value practices in oncology? [Internet]. JAMA Oncol. 2020;6:1693–4.

30. Moynihan R, Johannsson M, Maybee A, Lang E, Légaré F. COVID-19: an opportunity to reduce unnecessary healthcare [Internet]. The BMJ. 2020. https://doi.org/10.1136/bmj.m2752.

31. Pandemic Planning Clinical Guidance for Patients with Cancer. 2020.

32. The COVID-19 Multi-Model Comparison, Collaboration (CMCC) Policy Group. Guidance on use of modelling for policy responses to COVID-19 [Internet]. 2020 Aug [cited 2021 Jun 8]. Available from: https://decidehealthworld/cmcc.

33. Archer RA, Marshall AI, Sirinson K, Witthayapipopsakul W, Sriakkpokin P, Chootchongchatchai S, et al. Prioritizing critical-care resources in response to COVID-19: lessons from the development of Thailand’s Triage protocol. Int J Technol Assess Health Care [Internet]. 2020;36(6):540–4. https://doi.org/10.1017/S0266462320001890.

34. KS S, Faradiba D, Sittimart M, Isaranuwatchai W, Ananthakrishnan A, Rachanat C, et al. Factors associated with the covid-19 vaccination certificate: a multi-country observational study from Asia. Travel Med Infect Dis. 2022;48:102358.

35. Infodemic [Internet]. [cited 2021 Jun 9]. Available from: https://www.who.int/health-topics/infodemic#tab_1.

36. The Lancet Infectious Diseases. The COVID-19 Infodemic [Internet]. Vol. 20, The Lancet Infectious Diseases. Lancet Publishing Group, 2020 [cited 2021 Apr 9]. p. 875. Available from: https://www.youtube.com/.

37. Rzymski P, Borkowski L, Drag M, Fisliak R, Jemielity J, Krajewski J, et al. The strategies to support the COVID-19 vaccination with evidence-based communication and tackling misinformation. Vaccines [Internet]. 2021;9(2):1–9.

38. Vaccines | Special Issue - Health Technology Assessment (HTA) of New vaccines and New Target Groups and Impact Evaluation and Effectiveness of Current Vaccination Strategies [Internet]. [cited 2021 Jun 8]. Available from: https://www.mdpi.com/journal/vaccines/special_issues/HTA_vaccines.

39. Carley S, Horner D, Body R, Mackway-Jones K. Evidence-based medicine and COVID-19: what to believe and when to change. Emerg Med J [Internet]. 2020;37(9):572–5.

40. Nemzoff C, Ruiz F, Chalkidou K, Mehdiratta A, Guinness L, Chaula W, et al. Adaptive health technology assessment to facilitate priority setting in low- and middle-income countries [Internet]. BMJ Glob Health. 2021;6:6549.

41. Blüher M, Saunders SJ, Mittard V, Torrejon Torres R, Davis JA, Saunders R. Critical Review of European Health-Economic Guidelines for the Health Technology Assessment of Medical Devices. Front Med. 2019;29:278.

42. Uzochukwu BSC, Okeke C, O’Brien N, Ruiz F, Sombie I, Hollingsworth S. Health technology assessment and priority setting for universal health coverage: a qualitative study of stakeholders’ capacity, needs, policy areas of demand and perspectives in Nigeria. Glob Health. 2020;16(1):1–11. https://doi.org/10.1186/s12992-020-00583-2.

43. Tjarnhøj-Thomsen T, Hansen HP. Knowledge in health technology assessment: who, what, how? Int J Technol Assess Health Care [Internet]. 2011;27(4):324–9.

44. Oortwijn W, Husereau D, Abelson J, Barasa E, Bayani DD, Santos VC. Designing and implementing deliberative processes for health technology assessment: a good practices report of a Joint HTA/SPOR task force. Int J Technol Assess Health Care [Internet]. 2022;38(1):37.

45. Pacific WHORD for the W. Factors conducive to the development of health technology assessment in Asia: impacts and policy options [Internet]. Manila: WHO Regional Office for the Western Pacific, 2015. (Policy brief vol.4, no.2). Available from: https://iris.wpro.who.int/handle/10665/1/12588.

46. Baum F, Freeman T, Musolino C, Abramovitz M, De Ceukelaire W, Flavel J, et al. Explaining covid-19 performance: What factors might predict national responses? BMJ [Internet]. 2021;372.

47. Bump JB. What Really Sets Priorities? Method, Context, and Perspective from 150 Years of Priority-Setting. In: Global Health Priority-Setting. Oxford University Press; p. 45–66.

48. Teeravattananon Y, Sarin KC, Chi Y-L, Diabek S, Kazibwe J, Clapham H. Recalibrating the notion of policymaking during pandemics. Epidemiics [Internet]. 2022;38:100552.

49. Elvidge J, Summerfield A, Knies S, Németh B, Kaló Z, Göettisch W, Dawoud D. Best-practice guidance for the health technology assessment of diagnostics and treatments for COVID-19. 2021. Zenodo. https://doi.org/10.5281/zenodo.5530468.

50. Painter C, Isaranuwatchai W, Prawjaeng J, Wee HL, Chua BWB, Huyh VN. Avoiding trouble ahead: lessons learned and suggestions for economic evaluations of COVID-19 vaccines. Appl Health Econ Health Policy [Internet]. 2021;19(4):463–72. https://doi.org/10.1007/s40258-021-00661-5.

51. French G, Hulse M, Nguyen D, Sobotka K, Webster K, Corman J, et al. Impact of hospital strain on excess deaths during the COVD-19 pandemic-United States, July 2020–July 2021. Am J Transplant. 2022;22(2):654–7.

52. Durance-Bagale A, Manzouk M, Ananthakrishnan A, Nagashima-Hayashi M, Lam ST, Sittrum M, et al. Science is only half of it: expert perspectives on operationalising infectious disease control cooperation in the ASEAN region. PLos Glob Public Heal [Internet]. 2022;22(5):1–18. https://doi.org/10.1371/journal.pggp.0000424.

53. Chalkidou K, Marten R, Cutler D, Culyer T, Smith R, Teerawattananon Y, et al. Health technology assessment in universal health coverage [Internet]. The Lancet. 2013;382:e48–9.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.